Summary of United Imaging Conference Call Company Overview - **Company**: United Imaging (688271.SS) - **Industry**: Medical Imaging Equipment - **Market Presence**: Expanded to over 90 countries worldwide Key Takeaways Industry Context - The period from 2023 to 2025 has been challenging for the medical device industry, particularly for multinational companies operating in China [2] - United Imaging has shown resilient revenue growth despite industry pressures, highlighting a divergence between domestic players and multinational peers due to better product competitiveness and cost efficiency [2] Operational Performance - The company maintains a strong focus on R&D investment to support both current platforms and future innovations [2] - Management emphasized a long-term strategy prioritizing R&D and market share over short-term profitability [3] International Expansion - Overseas revenue contribution is approximately 20%, with significant growth potential in North America and Europe [3] - The company has secured placements in prestigious institutions like Yale University and Massachusetts General Hospital, and is making progress in Germany [3] Policy Environment and Future Outlook - Industry volatility in recent years was largely due to policy implementation timing, with improvements noted in 2025 [4] - Management anticipates industry growth to normalize at around 6-8% in 2026, aligning with structural healthcare demand [4] Investment Thesis - United Imaging is positioned for long-term growth with increasing government funding and a rising market share in China [8] - The company is currently trading near its median P/E multiple since listing, with expected growth in revenue, gross profit margin (GPM), and net profit margin (NPM) [8] - Key catalysts for growth include upcoming hospital procurement data and the launch of a new ultrasound product line [8] Price Target and Risks - The 12-month target price is set at Rmb174, indicating a potential upside of 32.8% from the current price of Rmb131 [10] - Key risks include chip supply chain issues, raw material availability (especially helium), macroeconomic downturns in China, and potential volume-based procurement (VBP) risks [9] Additional Insights - Management remains confident in the company's competitive positioning and medium-term industry fundamentals [4] - The company is expected to benefit from a shift towards service-related revenue, which will enhance profitability [8]

Summary of United Imaging (688271.SS) FY25 Preliminary Results Conference Call Company Overview - **Company**: United Imaging - **Ticker**: 688271.SS - **Industry**: Medical Imaging Equipment Key Financial Highlights - **FY25 Preliminary Results**: - Revenue: Rmb 13,821 million, representing a **34% year-over-year (yoy)** increase [1] - Net Profit: Rmb 1,888 million, reflecting a **50% yoy** growth [1] - 4Q25 Revenue Growth: Implied **48% yoy** growth [1] - Anticipated growth for 4Q25: - Domestic Business: **44% yoy** - Overseas Business: **61% yoy** - Full Year FY25E Growth: - Domestic: **30% yoy** - Overseas: **49% yoy** [2] Factors Contributing to Performance 1. Continuous launch of innovative products, including high-end equipment like PCCT and ultrasound product line [1] 2. Rapid growth in overseas business due to increased market recognition and improved global marketing and service systems [1] 3. Successful promotion of domestic trade-in policies [1] Revenue Distribution by Geography - **China Domestic Revenue**: - 1H25A: Rmb 4,873 million (10.7% yoy) - 3Q25A: Rmb 1,993 million (73.3% yoy) - 4Q25E: Rmb 3,578 million (44.1% yoy) - FY25E: Rmb 10,444 million (30.0% yoy) [2] - **Overseas Revenue**: - 1H25A: Rmb 1,142 million (22.4% yoy) - 3Q25A: Rmb 851 million (80.7% yoy) - 4Q25E: Rmb 1,383 million (60.5% yoy) - FY25E: Rmb 3,376 million (49.0% yoy) [2] Future Outlook and Adjustments - Despite strong preliminary results, the company’s 2026E revenue forecast remains unchanged due to high base pressure from hospital bidding in China in 1H26 [2] - Continuous optimism about the company’s growth due to innovative products, overseas expansion, and increasing recurring revenue proportion [2] Investment Thesis - United Imaging is a leading manufacturer in the medical imaging equipment sector, with a growing market share and increasing government funding support for medical equipment procurement in China [7] - Anticipated rise in service-related revenue is expected to improve gross profit margins (GPM) [7] - Current trading near median P/E multiple since listing, with significant long-term growth potential due to expected revenue and profit margin growth [7] Price Target and Risks - **12-Month Price Target**: Rmb 174, indicating a **36.9% upside** from the current price of Rmb 127.08 [9] - Key Risks: - Chip supply chain disruptions - Raw material risks, particularly helium - Macroeconomic downturns in China - Potential Value-Based Pricing (VBP) risks [8] Conclusion - United Imaging's strong performance in FY25, driven by innovative products and overseas expansion, positions it well for future growth despite potential risks. The company maintains a "Buy" rating with a favorable price target reflecting its growth potential.